Benzinga

Benzinga

Benzinga

mercoledì, agosto 26

Werewolf Therapeutics Inc

HOWLNASDAQ
Trade with Public
Trade with Public
$0.9500
0.066.74%
Ult. Agg.: Aug 26, 3:15 PM
Fusioni e acquisizioni: Ambros Therapeutics, Inc announced it will be merged with Werewolf Therapeutics (HOWL) on Friday, August 21, 2026 for $47.5M paid in stock
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Werewolf Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Werewolf Therapeutics (HOWL).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

1S.Buy
3Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+584.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Dec 19, 2025HC Wainwright & Co.Andres Y. MaldonadoPT CutBuy$10→$4
Nov 18, 2025B of A SecuritiesJason ZemanskyPT CutBuy$8→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $10 to $4.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $8 to $7.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $9 to $8.
Benzinga Newsdesk

PRO
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3

JMP Securities analyst Reni J. Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $8 to $6.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

Wedbush analyst Robert Driscoll reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and maintains $8 price target.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved